Clinical trial
Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients…
NCT00326469 · Ipsen, Industry · Completed
Key facts
| NCT number | NCT00326469 |
|---|---|
| Title | Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours |
| Official title | Phase II, Open, Single Group, Multicentre Study to Evaluate the Efficacy and Safety of Lanreotide Autogel Administered Every 4 Weeks by Deep Subcutaneous Injection in the Tumour's Growth Stabilization of Patients With Progressive Neuroendocrine Tumours Who Are Not Eligible to be Treated With Either… |
| Lead sponsor | Ipsen, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Neuroendocrine Tumours |
| Intervention type | Drug |
| Interventions | lanreotide (Autogel formulation) |
| Enrollment | 30 |
| Start date | May 1, 2006 |
| Primary completion | Nov 1, 2009 |
| Completion | Nov 1, 2009 |
| First posted | May 16, 2006 |
| Last update posted | Nov 5, 2020 |
| Countries | Spain |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: